

David Ternant

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9105896/publications.pdf>

Version: 2024-02-01

77
papers

3,073
citations

201385

27
h-index

161609

54
g-index

79
all docs

79
docs citations

79
times ranked

3446
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial. <i>Gastroenterology</i> , 2008, 134, 1861-1868. | 0.6 | 477 |
| 2 | Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 948-55. | 3.8 | 301 |
| 3 | Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 523-529. | 1.0 | 172 |
| 4 | Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2011, 13, R105. | 1.6 | 134 |
| 5 | Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. <i>Blood</i> , 2009, 113, 3765-3772. | 0.6 | 116 |
| 6 | Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, S37-S47. | 1.4 | 108 |
| 7 | An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Infliximab. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 169-174. | 1.0 | 93 |
| 8 | Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 6329-6337. | 3.2 | 92 |
| 9 | Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis. <i>Clinical Pharmacokinetics</i> , 2015, 54, 1107-1123. | 1.6 | 84 |
| 10 | Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. <i>Blood</i> , 2017, 129, 2616-2623. | 0.6 | 73 |
| 11 | Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 118-128. | 1.1 | 68 |
| 12 | Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. <i>MAbs</i> , 2015, 7, 1205-1211. | 2.6 | 67 |
| 13 | Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 286-297. | 1.1 | 66 |
| 14 | Trough Infliximab Concentrations Predict Efficacy and Sustained Control of Disease Activity in Rheumatoid Arthritis. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 232-236. | 1.0 | 65 |
| 15 | An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 597-601. | 1.0 | 57 |
| 16 | IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding. <i>Journal of Immunology</i> , 2016, 196, 607-613. | 0.4 | 55 |
| 17 | The underlying inflammatory chronic disease influences infliximab pharmacokinetics. <i>MAbs</i> , 2016, 8, 1407-1416. | 2.6 | 54 |
| 18 | Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn's Disease. <i>Clinical Pharmacokinetics</i> , 2015, 54, 551-562. | 1.6 | 50 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 55-65. | 1.1 | 47 |
| 20 | Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1381-1394. | 1.6 | 46 |
| 21 | Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. <i>Arthritis Research and Therapy</i> , 2011, 13, R82. | 1.6 | 37 |
| 22 | Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. <i>RMD Open</i> , 2020, 6, e001047. | 1.8 | 36 |
| 23 | Pharmacokinetics of adalimumab in Crohn's disease. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1155-1157. | 0.8 | 35 |
| 24 | Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: Results of a randomized trial. <i>Transplant Immunology</i> , 2013, 28, 120-126. | 0.6 | 34 |
| 25 | An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 647-652. | 1.0 | 33 |
| 26 | Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 108-113. | 2.9 | 31 |
| 27 | Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, e151-e155. | 0.8 | 30 |
| 28 | Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications. <i>Clinical Pharmacokinetics</i> , 2020, 59, 857-874. | 1.6 | 29 |
| 29 | Should anti-TNF drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?. <i>Joint Bone Spine</i> , 2012, 79, 109-112. | 0.8 | 27 |
| 30 | Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1773-1781. | 1.1 | 27 |
| 31 | Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans. <i>Clinical Pharmacokinetics</i> , 2019, 58, 169-187. | 1.6 | 27 |
| 32 | Towards an individualised target concentration of adalimumab in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1428-1429. | 0.5 | 25 |
| 33 | Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review. <i>Clinical Pharmacokinetics</i> , 2020, 59, 37-49. | 1.6 | 25 |
| 34 | Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 941-948. | 1.1 | 24 |
| 35 | P2X7 Receptor Promotes Mouse Mammary Cancer Cell Invasiveness and Tumour Progression, and Is a Target for Anticancer Treatment. <i>Cancers</i> , 2020, 12, 2342. | 1.7 | 24 |
| 36 | Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacodynamic Modeling. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 322-326. | 1.0 | 23 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Dose " response relationship of bevacizumab in hereditary hemorrhagic telangiectasia. <i>MABs</i> , 2015, 7, 630-637. | 2.6 | 21 |
| 38 | Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 364-369. | 1.0 | 21 |
| 39 | Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. <i>Clinical Pharmacokinetics</i> , 2017, 56, 635-647. | 1.6 | 21 |
| 40 | Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 597-605. | 1.1 | 20 |
| 41 | Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 561-573. | 1.1 | 19 |
| 42 | Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 567-572. | 1.0 | 19 |
| 43 | 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia. , 2019, 7, 22. | | 19 |
| 44 | A robust estimation of infliximab pharmacokinetic parameters in Crohn's disease. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1541-1542. | 0.8 | 15 |
| 45 | Modeling Immunization To Infliximab in Children With Crohn's Disease Using Population Pharmacokinetics: A Pilot Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1745-1754. | 0.9 | 15 |
| 46 | A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen. <i>BMC Cancer</i> , 2017, 17, 220. | 1.1 | 14 |
| 47 | Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1173-1184. | 1.6 | 14 |
| 48 | Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: A pilot study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2002-2010. | 1.1 | 14 |
| 49 | Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 339-343. | 1.0 | 13 |
| 50 | Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study. <i>Pharmaceuticals</i> , 2021, 14, 796. | 1.7 | 13 |
| 51 | CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2747-2758. | 1.1 | 12 |
| 52 | Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited. <i>Clinical Pharmacokinetics</i> , 2020, 59, 519-530. | 1.6 | 12 |
| 53 | Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 26-34. | 0.7 | 11 |
| 54 | A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS). <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 253-255. | 0.8 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Interindividual variability in the concentrationâ€”effect relationship of antilymphocyte globulinsâ€”a possible influence of FcÎ³RIIIa genetic polymorphism. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 60-68. | 1.1 | 10 |
| 56 | Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2236-2246. | 1.1 | 10 |
| 57 | Development and validation of an enzyme-linked immunosorbent assay to measure free eculizumab concentration in serum. <i>Bioanalysis</i> , 2017, 9, 1227-1235. | 0.6 | 9 |
| 58 | Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study. <i>Haematologica</i> , 2018, 103, e356-e359. | 1.7 | 7 |
| 59 | CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen. <i>Transplant International</i> , 2016, 29, 184-195. | 0.8 | 6 |
| 60 | New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 722-728. | 1.1 | 6 |
| 61 | Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 210-219. | 2.3 | 6 |
| 62 | Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer. <i>Clinical Nutrition</i> , 2020, 39, 3319-3330. | 2.3 | 5 |
| 63 | The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. <i>Clinical Pharmacokinetics</i> , 2022, 61, 423-437. | 1.6 | 5 |
| 64 | Gota et al. on their article â€œthe pharmacokinetics of Redituxâ„¸, a biosimilar of rituximabâ€¸. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1317-1318. | 1.1 | 4 |
| 65 | Food and lipid intake alters the pharmacokinetics of cyclosporine in kidney transplants. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 446-454. | 1.0 | 4 |
| 66 | Therapeutic Antibodies for the Treatment of Respiratory Tract Infectionsâ€”Current Overview and Perspectives. <i>Vaccines</i> , 2021, 9, 151. | 2.1 | 4 |
| 67 | Infliximab Treatment Does Not Lead to Full TNF-Î± Inhibition: A Target-Mediated Drug Disposition Model. <i>Clinical Pharmacokinetics</i> , 2022, 61, 143-154. | 1.6 | 4 |
| 68 | Development and validation of an ELISA to study panitumumab pharmacokinetics. <i>Bioanalysis</i> , 2018, 10, 205-214. | 0.6 | 3 |
| 69 | Pharmacokinetics partly explains the relationship between carcinoembryonic antigen level and survival of colorectal cancer patients treated with ramucirumab. <i>European Journal of Cancer</i> , 2018, 92, 119-120. | 1.3 | 3 |
| 70 | Letter to Dreesen et al. on their article â€œModelling of the Relationship Between Infliximab Exposure, Faecal Calprotectin, and Endoscopic Remission in Patients With Crohn's Diseaseâ€¸” A comprehensive review of infliximab population pharmacokinetic modelling publications. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1594-1595. | 1.1 | 2 |
| 71 | A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations. <i>Bioanalysis</i> , 2021, 13, 565-574. | 0.6 | 2 |
| 72 | Association of IgG1 Antibody Clearance with FcÎ³RIIA Polymorphism and Platelet Count in Infliximab-Treated Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6051. | 1.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Infliximab Efficacy May Be Linked to Full TNF- α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model. <i>Pharmaceutics</i> , 2021, 13, 1821. | 2.0 | 2 |
| 74 | Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target-mediated drug disposition model. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3500-3505. | 1.1 | 2 |
| 75 | Intravenous and subcutaneous administration of trastuzumab in a patient on peritoneal dialysis. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3372-3374. | 1.1 | 1 |
| 76 | Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2021, , 1. | 1.6 | 0 |
| 77 | Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study. <i>Leukemia and Lymphoma</i> , 2021, 62, 3160-3169. | 0.6 | 0 |